Safety and Side Effects in SARS-CoV-2 Vaccine
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Efficacy and Safety".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 101
Special Issue Editors
Interests: pharmacodynamics; infectious disease; epidemiological modeling; indoor control modeling of infectious disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
COVID-19 vaccines are important in the global battle against the SARS-CoV-2 pandemic. The swift development and distribution of COVID-19 vaccines, including mRNA (Pfizer-BioNTech, Moderna), viral vector (AstraZeneca, Johnson & Johnson, Sputnik V), and protein subunit (Novavax) vaccines, or inactivated virus (Sinovac, Sinopharm) vaccines, have been unprecedented. Although the benefits of vaccination in reducing COVID-19-induced illness and death are well documented, it is important to monitor and understand vaccines’ potential side effects. This Special Issue invites research papers and reviews that enhance current understanding of these vaccines' safety and side effects, focusing on special populations (e.g., the elderly and children, pregnant and lactating women, and immunocompromised individuals) and rare adverse events. Understanding these aspects is critical for healthcare providers and policymakers to improve vaccine confidence and optimize public health strategies. We also welcome articles on vaccine safety monitoring systems, e.g., the vaccine adverse event reporting system (VAERS) and the vaccine safety datalink (VSD). While these systems ensure ongoing assessment, it is essential to understand the effectiveness and transparency in different local or geographic regions. We look forward to receiving your research articles, including reviews, real-world data, meta-analyses, opinions, or surveys.
Dr. Ying-Fei Yang
Dr. Sher Singh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19 vaccine
- vaccine adverse event reporting system (VAERS)
- vaccine safety datalink (VSD)
- adverse event
- safety and side effects
